कृपया अन्य खोज का प्रयास करें
BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company’s development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson’s disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Michael Brennan | 51 | 2013 | Co-Founder & Non-Executive Director |
Olivier Brandicourt | 68 | 2022 | Independent Non-Executive Director |
Nigel Shadbolt | - | 2022 | Independent Non-Executive Director |
Marcello Damiani | 53 | 2023 | Independent Non-Executive Director |
Susan Liautaud | - | 2022 | Independent Non-Executive Director |
John Jacob Orloff | 67 | 2022 | Independent Non-Executive Director & Workforce Non-Executive Director |
Jean Raby | 59 | 2022 | Senior Independent Non-Executive Director |
Francois Nader | 68 | 2022 | Independent Non-Executive Chairman |
Joerg Moeller | - | 2024 | CEO & Executive Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है